Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RENEW-Op-1: Brenipatide + Buprenorphine in Opioid Use Disorder
NCT07420283Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Countries
- 4
01
Overview
A Phase 2 trial of brenipatide in opioid use disorder (OUD), sponsored by Eli Lilly and Company. Started Feb 2026; status: recruiting.
02
Drugs
brenipatide
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT07420283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07420283.